Braeburn Conventional Debt · $110M raised · (2018)

Braeburn Pharmaceuticals is focused on developing long-acting implantable and injectable therapies for opioid addiction and chronic pain. Their lead product, Probufine (buprenorphine implant), is FDA-approved for opioid dependence, and another product, CAM2038, is in the NDA refilling process for opioid dependence and in Phase 3 for pain management. The company aims to transform the management of opioid use disorder by eliminating stigma and improving access to treatment.